Business Description
Nanexa AB
ISIN : SE0007074166
Total Employee Number:
16Compare
Compare
Traded in other countries / regions
NANEXA.Sweden40M.Germany IPO Date
2015-06-17Description
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries, while it also has its presence in Europe (excluding the Nordic countries), North America, and Asia.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 66.11 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.09 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 21.07 | |||||
Beneish M-Score | -2.8 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 55 | |||||
3-Year EPS without NRI Growth Rate | 60.8 | |||||
3-Year FCF Growth Rate | 43.8 | |||||
3-Year Book Growth Rate | -33.8 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 64.32 | |||||
9-Day RSI | 63.36 | |||||
14-Day RSI | 63.03 | |||||
3-1 Month Momentum % | -0.12 | |||||
6-1 Month Momentum % | 1.51 | |||||
12-1 Month Momentum % | 78.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.89 | |||||
Quick Ratio | 2.89 | |||||
Cash Ratio | 2.5 | |||||
Days Sales Outstanding | 67.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -47.5 | |||||
Shareholder Yield % | -7.67 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 152.64 | |||||
Operating Margin % | -67.39 | |||||
Net Margin % | -72.54 | |||||
EBITDA Margin % | -27.59 | |||||
FCF Margin % | -99.74 | |||||
OCF Margin % | -19.01 | |||||
ROE % | -23.22 | |||||
ROA % | -17.54 | |||||
ROIC % | -21.47 | |||||
3-Year ROIIC % | 1956.04 | |||||
ROC (Joel Greenblatt) % | -207.08 | |||||
ROCE % | -19.45 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 22.86 | |||||
PB Ratio | 6.68 | |||||
Price-to-Tangible-Book | 17.14 | |||||
EV-to-EBIT | -37.36 | |||||
EV-to-EBITDA | -89.43 | |||||
EV-to-Revenue | 24.67 | |||||
EV-to-FCF | -24.74 | |||||
Price-to-GF-Value | 2.4 | |||||
Price-to-Median-PS-Value | 0.34 | |||||
| Price-to-Net-Current-Asset-Value | 22.86 | |||||
| Price-to-Net-Cash | 28.24 | |||||
Earnings Yield (Greenblatt) % | -2.68 | |||||
FCF Yield % | -3.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nanexa AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 33.853 | ||
| EPS (TTM) (kr) | -0.13 | ||
| Beta | 1.3165 | ||
| 3-Year Sharpe Ratio | 0.48 | ||
| 3-Year Sortino Ratio | 1.11 | ||
| Volatility % | 167.17 | ||
| 14-Day RSI | 63.03 | ||
| 14-Day ATR (kr) | 0.277033 | ||
| 20-Day SMA (kr) | 4.48375 | ||
| 12-1 Month Momentum % | 78.98 | ||
| 52-Week Range (kr) | 1.4 - 5 | ||
| Shares Outstanding (Mil) | 184.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nanexa AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nanexa AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Fourth quarter earnings results for 2026 | 2027-02-19 | In 175 days | ||
| Third quarter earnings results for 2026 | 2026-10-21 | In 54 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-27 13:00 | 4.52 (-3.94%) | ||
| Second quarter earnings results for 2026 | 2026-08-27 | 4.52 (-3.94%) | ||
| General meeting for 2025 | 2026-05-12 15:00 | 3.58 (-0.56%) | ||
| First quarter earnings results for 2026 | 2026-04-29 | 3.76 (-1.05%) | ||
| Annual report for 2025 | 2026-03-26 | 3.68 (+2.08%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-19 | 3.60 (+0.28%) | ||
| Third quarter earnings results for 2025 | 2025-10-21 | 1.90 (-2.57%) | ||
| Second quarter earnings results for 2025 | 2025-08-27 | 2.27 (+2.25%) |
Show
Entries
Nanexa AB Frequently Asked Questions
What is Nanexa AB(OSTO:NANEXA)'s stock price today?
The current price of OSTO:NANEXA is kr4.80. The 52 week high of OSTO:NANEXA is kr5.00 and 52 week low is kr1.40.
When is next earnings date of Nanexa AB(OSTO:NANEXA)?
The next earnings date of Nanexa AB(OSTO:NANEXA) is 2026-10-21 Est..
Does Nanexa AB(OSTO:NANEXA) pay dividends? If so, how much?
Nanexa AB(OSTO:NANEXA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Nanexa AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers